Temozolomide Suppliers & Bulk Manufacturers

Available Forms: Oral Tablets and Oral Capsules

Available Strengths: Capsules: 5 mg, 20 mg, 100 mg, 140 mg; Tablets: 250 mg

Reference Brands: Temodar® (US & EU)

Category: Oncology Cancer Care

Temozolomide (brand name Temodar®) is an oral chemotherapy used for glioblastoma multiforme (GBM) and anaplastic astrocytoma. Available in 5 mg, 20 mg, 100 mg, 140 mg, and 250 mg strengths, it is approved in both the US and EU. Manufactured under GMP standards, Temozolomide is a key oncology treatment for global B2B pharmaceutical distribution. Temozolomide is available in Oral Tablets and Oral Capsules and strengths such as Capsules: 5 mg, 20 mg, 100 mg, 140 mg; Tablets: 250 mg. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Temozolomide is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.

Temozolomide can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.

Product Description: Temozolomide is an oral chemotherapy agent used in the treatment of glioblastoma multiforme (GBM) and anaplastic astrocytoma, two aggressive brain cancers. Temozolomide works by damaging cancer cell DNA, preventing replication and inducing cell death. Available in 5 mg, 20 mg, 100 mg, 140 mg, and 250 mg strengths, it is marketed under the brand name Temodar® by Merck in both the US and EU. Manufactured under GMP-compliant facilities, it offers a reliable treatment option for oncology-focused pharmaceutical partners, providing a vital oral chemotherapy solution in the global cancer treatment market.